In the last ten years FDA made 5 decisions for Nyxoah (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (3). The latest was on 2026-07-30.
The competitor scorecard in each family (innovation pace, recall and report signals, commercial momentum, financial capacity), every decision on record, open recalls, MAUDE report trends against the category and quarterly financials come with the product and company coverage add-on, $29/mo on any paid plan.
See the add-on